Nevertheless, evidence suggests that ixekizumab is strongly associated with the onset of IBD.[3–6] Guselkumab (GUS), a fully human IgG1λ monoclonal antibody, is a selective inhibitor of the IL-23p19 subunit. The gene discussed is IL23A; the disease is inflammatory bowel disease.